04- PHARMA/BIOTECH

I know we’re in the business of making and selling drugs to patients but this is worrying Rosanna O’Connor’s, Public Health England, review will be interesting <<<Hooked>>>

Another antibody targeting Tau protein for the treatment of AD! <<LINK>>

Bryostatin’s mechanism of action is to modulate protein kinase activity  (pka) and reduces amyloid and tau apparently Still doesn’t work >>> LINK<<<

I really don’t get this! What about all the other confounding factors??? >>> LINK <<<

If there’s anything novel about your programme? Then it’s a no brainer !!! >>> <<LINK>>>

It’s about time the government (NICE) tightened up on Pharma pricing of drugs! >>LINK<<

AC Immune’s crenezumab already has one Phase III trial in progress now they’ve started another. All based on their ‘failed’ Phase II study. Where’s the sense – or is it just me >> http://www.fiercebiotech.com/r-d/roche-starts-second-alzheimer-s-phase-3-anti-abeta-drug?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiTkdJMFpUZzFaakkwTmpBeCIsInQiOiJoVWxqQ2tsbFVjSjlWSThTK3pZM2lHTFY0TTI3NGVSamFqUjRINnVCdzlZdkM0S0RwODBzU0hleTZmckg4QjcyaEFwSVhSOHd3XC9xUnZ5TWNGTzZweWordllsZU9EZ2pOVWVSSHRLNnJqTWpEekl4eWkweHpEejN2Y2xEcTlVYzIifQ%3D%3D

Did they really think this was going to work in the first place A triglyceride and a re-formulation with less bioavailability post Phase II Who funds these ideas! >> More Phase 3 disappointment in Alzheimer’s disease  

Very interesting new press release No idea why the Intercept share price went down given that it’ll be much easier now to get a positive trial result with statistical significance on only one or other of the co-primary endpoints and it’s reduced the number of subjects required in total as well! It certainly does raise […]

And you wonder why pharma have a bad name Some of these companies you might expect but not Pfizer They were very sneaky selling to Flynn and getting them to increase the price of phenytoin for epilepsy by 2600% ! I bet the £84m fine didn’t hurt too much! >>>> http://www.thetimes.co.uk/article/duplicate-permits-let-manufacturers-keep-their-dominance-fsrkp3lnq?shareToken=fdb66b66afe630645809670d8992a145